Paris, France – Advesya, a company dedicated to developing novel therapies targeting IL-1RAP, announced that it will present two posters at the 66th American Society of Hematology (ASH) Annual Meeting, to be held in San Diego, California, from December 7 to 10, 2024.
First Poster Presentation:
Our collaborators at ALFA (Acute Leukemia French Association) will present new data demonstrating the clear expression of IL-1RAP on malignant blasts and leukemic stem cells in the majority of patients with relapsed/refractory acute myeloid leukemia (AML). This translational research further validates the therapeutic potential of IL-1RAP in addressing an area with significant unmet medical need.
Poster Title:
4311 IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, Translational Research, Diseases, Treatment Considerations, Biological therapies, Myeloid Malignancies
Second Poster Presentation:
The second poster will outline the design of the Resolve AML 001 study, an adaptive, open-label, multicenter Phase 1/2 trial. This study aims to determine the recommended Phase 2 dose of CCTx-001, a third-generation autologous CAR T-cell therapy under development for the treatment of patients with refractory and resistant AML.
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
🔬 The posters will be made available on our website following the conference.
